Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.
Separately, HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th.
Read Our Latest Research Report on Aclaris Therapeutics
Aclaris Therapeutics Stock Performance
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The company had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. Research analysts predict that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Aclaris Therapeutics in the 1st quarter valued at $39,000. BNP Paribas Financial Markets raised its holdings in shares of Aclaris Therapeutics by 10.9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 23,747 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 13,461 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 61,602 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock worth $6,113,000 after purchasing an additional 207,418 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Read More
- Five stocks we like better than Aclaris Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- What Is WallStreetBets and What Stocks Are They Targeting?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.